


Supplementary Figure 5



Supplementary Figure 5: Subpopulation-specific BCL-2 family levels and time on 5-AZA/VEN

A-B MAC-Score of AML patients from **A** cohort 1 (n=17) and **B** cohort 2 (n=18) with 5-AZA/VEN therapy outcome.

C-D Event-free survival of first-line 5-AZA/VEN AML patients from **C** cohort 1 and **D** cohort 2 with above (>0.4) and below (<0.4) median MAC-Score.

E-H Event-free survival of first-line 5-AZA/VEN AML patients from cohorts 1 and 2 combined with above and below median **E** MAC-Score, **F** BCL-2 expression, **G** MCL-1 expression and **H** BCL-xL expression in *LSC-like*, *non-LSC*, *Mature* and total blast cells. LSC: Leukemic stem cell, MAC-Score: Mediators of Apoptosis Combinatorial Score, 5-AZA: Azacitidine, VEN: Venetoclax